Is bortezomib active in patients with mantle cell lymphoma?

被引：0
|
作者：
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenspital Stadt Wien, Dept Med 1, Ctr Oncol & Haematol, A-1171 Vienna, Austria
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 05期
关键词：
bortezomib; mantle cell lymphoma; response; toxicity;
D O I：
10.1038/ncponc0789
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：276 / 277
页数：2
相关论文
共 50 条
  • [21] The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
    Arkwright, Richard
    Tri Minh Pham
    Zonder, Jeffrey A.
    Dou, Q. Ping
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (02) : 225 - 235
  • [22] Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
    Perez-Galan, Patricia
    Mora-Jensen, Helena
    Weniger, Marc A.
    Shaffer, Arthur L., III
    Rizzatti, Edgar G.
    Chapman, Colby M.
    Mo, Clifton C.
    Stennett, Lawrence S.
    Rader, Christoph
    Liu, Poching
    Raghavachari, Nalini
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Pittaluga, Stefania
    Maric, Irina
    Dunleavy, Kieron M.
    Wilson, Wyndham H.
    Staudt, Louis M.
    Wiestner, Adrian
    BLOOD, 2011, 117 (02) : 542 - 552
  • [23] The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
    Uziel, Orit
    Cohen, Olga
    Beery, Einat
    Nordenberg, Jardena
    Lahav, Meir
    TRANSLATIONAL ONCOLOGY, 2014, 7 (06) : 741 - 751
  • [24] Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation
    Paul L. McCormack
    BioDrugs, 2015, 29 : 207 - 214
  • [25] Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation
    McCormack, Paul L.
    BIODRUGS, 2015, 29 (03) : 207 - 214
  • [26] Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma
    O'Connor, Owen A.
    CLINICAL LYMPHOMA & MYELOMA, 2005, 6 (03): : 191 - 199
  • [27] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [28] Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    Gerecitano, John
    Portlock, Carol
    Moskowitz, Craig
    Hamlin, Paul
    Straus, David
    Zelenetz, Andrew D.
    Zhang, Zhigang
    Dumitrescu, Otilia
    Sarasohn, Debra
    Lin, Dorothy
    Pappanicholaou, Jennifer
    Cortelli, Barbara M.
    Neylon, Ellen
    Hamelers, Rachel
    Wright, John
    O'Connor, Owen A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (06) : 652 - 655
  • [29] Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
    Paoluzzi, Luca
    Scotto, Luigi
    Marchi, Enrica
    Zain, Jasmine
    Seshan, Venkatraman E.
    O'Connor, Owen A.
    CLINICAL CANCER RESEARCH, 2010, 16 (02) : 554 - 565
  • [30] Bortezomib-Based Therapy for Mantle-Cell Lymphoma REPLY
    Cavalli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (23): : 2271 - 2271
12345